American Century Companies Inc. Purchases 48,286 Shares of Biohaven Ltd. (NYSE:BHVN)

American Century Companies Inc. boosted its position in Biohaven Ltd. (NYSE:BHVN - Free Report) by 9.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 558,761 shares of the company's stock after buying an additional 48,286 shares during the quarter. American Century Companies Inc. owned approximately 0.55% of Biohaven worth $20,870,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in BHVN. Stifel Financial Corp lifted its stake in shares of Biohaven by 0.4% during the 3rd quarter. Stifel Financial Corp now owns 6,509,261 shares of the company's stock valued at $325,268,000 after buying an additional 28,684 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Biohaven by 5.6% during the 3rd quarter. Janus Henderson Group PLC now owns 6,226,393 shares of the company's stock valued at $311,142,000 after acquiring an additional 328,099 shares during the period. Geode Capital Management LLC lifted its position in shares of Biohaven by 2.6% during the third quarter. Geode Capital Management LLC now owns 1,714,612 shares of the company's stock worth $85,696,000 after acquiring an additional 44,174 shares in the last quarter. Point72 Asset Management L.P. lifted its position in shares of Biohaven by 745.9% during the third quarter. Point72 Asset Management L.P. now owns 1,500,284 shares of the company's stock worth $74,969,000 after acquiring an additional 1,322,922 shares in the last quarter. Finally, ARS Investment Partners LLC boosted its holdings in shares of Biohaven by 1.0% in the fourth quarter. ARS Investment Partners LLC now owns 1,040,712 shares of the company's stock worth $38,871,000 after acquiring an additional 10,473 shares during the period. 88.78% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

BHVN has been the topic of a number of analyst reports. Royal Bank of Canada reiterated an "outperform" rating and set a $61.00 price objective on shares of Biohaven in a research note on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft set a $60.00 price target on Biohaven and gave the company a "buy" rating in a research report on Thursday, March 20th. Cantor Fitzgerald restated an "overweight" rating on shares of Biohaven in a research report on Tuesday, December 17th. HC Wainwright reaffirmed a "buy" rating and set a $54.00 target price on shares of Biohaven in a report on Tuesday, March 4th. Finally, Morgan Stanley cut their price target on shares of Biohaven from $69.00 to $63.00 and set an "overweight" rating for the company in a report on Friday, March 7th. Fourteen investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $62.77.

Insider Transactions at Biohaven

In related news, Director John W. Childs acquired 32,700 shares of Biohaven stock in a transaction dated Tuesday, March 4th. The shares were purchased at an average cost of $30.47 per share, with a total value of $996,369.00. Following the completion of the purchase, the director now owns 2,320,571 shares of the company's stock, valued at $70,707,798.37. This represents a 1.43 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 16.00% of the company's stock.

Biohaven Price Performance

NYSE BHVN traded down $3.16 during trading hours on Thursday, reaching $20.52. 2,681,782 shares of the stock traded hands, compared to its average volume of 1,092,197. The stock has a 50 day simple moving average of $33.81 and a two-hundred day simple moving average of $40.94. Biohaven Ltd. has a 1 year low of $20.41 and a 1 year high of $55.72. The company has a market cap of $2.09 billion, a price-to-earnings ratio of -2.19 and a beta of 1.33.

Biohaven (NYSE:BHVN - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.29). On average, sell-side analysts forecast that Biohaven Ltd. will post -8.9 EPS for the current fiscal year.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.